Journalartikel

Autorenliste: Hasseli, Rebecca; Hanses, Frank; Stecher, Melanie; Specker, Christof; Weise, Tobias; Borgmann, Stefan; Hasselberger, Martina; Hertenstein, Bernd; Hower, Martin; Hoyer, Bimba F.; Koll, Carolin; Krause, Andreas; von Lilienfeld-Toal, Marie; Lorenz, Hanns-Martin; Merle, Uta; Nunes de Miranda, Susana M.; Pletz, Mathias W.; Regierer, Anne C.; Richter, Jutta G.; Rieg, Siegbert; Roemmele, Christoph; Ruethrich, Maria M.; Schmeiser, Tim; Schulze-Koops, Hendrik; Strangfeld, Anja; Vehreschild, Maria J. G. T.; Voit, Florian; Voll, Reinhard E.; Vehreschild, Joerg Janne; Mueller-Ladner, Ulf; Pfeil, Alexander

Jahr der Veröffentlichung: 2024

Zeitschrift: Frontiers in Medicine

Bandnummer: 11

eISSN: 2296-858X

Open Access Status: Gold

DOI Link: https://doi.org/10.3389/fmed.2024.1332716

Verlag: Frontiers Media

Abstract: 
Objectives To investigate, whether inflammatory rheumatic diseases (IRD) inpatients are at higher risk to develop a severe course of SARS-CoV-2 infections compared to the general population, data from the German COVID-19 registry for IRD patients and data from the Lean European Survey on SARS-CoV-2 (LEOSS) infected patients covering inpatients from the general population with SARS-CoV-2 infections were compared. Methods 4310 (LEOSS registry) and 1139 cases (IRD registry) were collected in general. Data were matched for age and gender. From both registries, 732 matched inpatients (LEOSS registry: n = 366 and IRD registry: n = 366) were included for analyses in total. Results Regarding the COVID-19 associated lethality, no significant difference between both registries was observed. Age > 65(degrees)years, chronic obstructive pulmonary disease, diabetes mellitus, rheumatoid arthritis, spondyloarthritis and the use of rituximab were associated with more severe courses of COVID-19. Female gender and the use of tumor necrosis factor-alpha inhibitors (TNF-I) were associated with a better outcome of COVID-19. Conclusion Inflammatory rheumatic diseases (IRD) patients have the same risk factors for severe COVID-19 regarding comorbidities compared to the general population without any immune-mediated disease or immunomodulation. The use of rituximab was associated with an increased risk for severe COVID-19. On the other hand, the use of TNF-I was associated with less severe COVID-19 compared to the general population, which might indicate a protective effect of TNF-I against severe COVID-19 disease.

Harvard-Zitierstil: Hasseli, R., Hanses, F., Stecher, M., Specker, C., Weise, T., Borgmann, S., et al. (2024) The protective effect of tumor necrosis factor-alpha inhibitors in COVID-19 in patients with inflammatory rheumatic diseases compared to the general population-A comparison of two German registries, Frontiers in Medicine, 11, Article 1332716. https://doi.org/10.3389/fmed.2024.1332716

APA-Zitierstil: Hasseli, R., Hanses, F., Stecher, M., Specker, C., Weise, T., Borgmann, S., Hasselberger, M., Hertenstein, B., Hower, M., Hoyer, B., Koll, C., Krause, A., von Lilienfeld-Toal, M., Lorenz, H., Merle, U., Nunes de Miranda, S., Pletz, M., Regierer, A., Richter, J., ...Pfeil, A. (2024). The protective effect of tumor necrosis factor-alpha inhibitors in COVID-19 in patients with inflammatory rheumatic diseases compared to the general population-A comparison of two German registries. Frontiers in Medicine. 11, Article 1332716. https://doi.org/10.3389/fmed.2024.1332716